Who should not take CJC-1295 (no DAC)?
Documented caution flags for CJC-1295 (no DAC) include active malignancy and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for CJC-1295 (no DAC) is limited.
Documented caution flags for CJC-1295 (no DAC)
- Active malignancy
- Pregnancy / nursing
Reported side effects to weigh
- Head-rush
- Brief facial flush
- Hunger pulse
References
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295 — Teichman SL et al., JCEM, 2006
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Jetté L et al., Endocrinology, 2005
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — Villegas Meza AD et al., JBJS Reviews, 2026
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on CJC-1295 (no DAC)
Full CJC-1295 (no DAC) breakdownCJC-1295 (no DAC) what it's used forCJC-1295 (no DAC) side effectsCJC-1295 (no DAC) how to take itCJC-1295 (no DAC) mistakes to avoidCJC-1295 (no DAC) half-lifeCJC-1295 (no DAC) how long to workCJC-1295 (no DAC) legal statusCJC-1295 (no DAC) how it workscjc 1295 vs tesamorelinipamorelin vs cjc 1295cjc 1295 vs sermorelinAsk the AI Coach
Last updated 2026-06-15.